4.5 Article

CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration

Journal

BMJ-BRITISH MEDICAL JOURNAL
Volume 350, Issue -, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmj.h1793

Keywords

-

Funding

  1. Alberta Advanced Education and Technology
  2. Alberta Innovates - Health Solutions (AHIS)
  3. Boiron
  4. Afexa Life Sciences
  5. Hecht Foundation
  6. HEEL
  7. Pfizer USA
  8. Schwabe Pharma
  9. Canadian Institutes for Health Research [86766]
  10. AHIS
  11. MRC [MR/J004871/1] Funding Source: UKRI
  12. Cancer Research UK [16895] Funding Source: researchfish
  13. Medical Research Council [MR/J004871/1] Funding Source: researchfish

Ask authors/readers for more resources

N-of-1 trials are a useful tool for clinicians who want to determine the effectiveness of a treatment in a particular individual. The reporting of N-of-1 trials has been variable and incomplete, hindering their usefulness in clinical decision making and by future researchers. This document presents the CONSORT (Consolidated Standards of Reporting Trials) extension for N-of-1 trials (CENT 2015). CENT 2015 extends the CONSORT 2010 guidance to facilitate the preparation and appraisal of reports of an individual N-of-1 trial or a series of prospectively planned, multiple, crossover N-of-1 trials. CENT 2015 elaborates on 14 items of the CONSORT 2010 checklist, totalling 25 checklist items (44 sub-items), and recommends diagrams to help authors document the progress of one participant through a trial or more than one participant through a trial or series of trials, as applicable. Examples of good reporting and evidence based rationale for CENT 2015 checklist items are provided.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available